New directions in metastatic mutated NSCLC
zipalertinib, a highly selective EGFR inhibitor, demonstrates meaningful intracranial activity in patients with EGFR exon 20 insertions and other uncommon mutations, including those with active CNS metastases
This commentary reviews recent abstract data from the ESMO Congress 2025 highlighting emerging therapies for metastatic mutated non‑small cell lung cancer (NSCLC). It summarizes intracranial efficacy of zipalertinib in EGFR exon 20ins and other rare EGFR mutations, updated survival from the PHAROS study of encorafenib plus binimetinib for BRAF V600E‑mutant NSCLC, activity of novel immunomodulators (TIGIT, CD27, ILT3/4, TLR7/8 agonist EIK1001) added to chemo‑immunotherapy, and recent developments with HER2‑mutant agents (zongertinib, sevabertinib, trastuzumab deruxtecan). The article underscores the rapidly evolving therapeutic landscape and the need for sequencing strategies, CNS‑active agents, and real‑world validation.
The information offers clinicians a snapshot of cutting‑edge therapeutic options, informs treatment sequencing decisions, and highlights gaps in evidence that will shape future clinical trials and guideline recommendations for metastatic mutated NSCLC.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT